(±)-Acenocoumarol

This product contains acenocoumarol (C19H15NO6). Molecular formula: C19H15NO6 Molecular weight: 353.34

1. Drugs that can enhance the anticoagulant effect when used in combination with this product include: ⑴ drugs that can compete with this product for plasma protein binding, thereby increasing the free amount of di-coumarin, such as aspirin, phenylbutazone, hydroxyphenylbutazone, mefenamic acid, chloral hydrate, clofibrate (clofibrate), sulfonamides, probenecid, etc.; ⑵ drugs that inhibit liver microsomal enzymes, thereby reducing the metabolism of this product and increasing its efficacy, such as chloramphenicol, allopurinol, monoamine oxidase inhibitors, metronidazole (metronidazole), cimetidine, etc.; ⑶ drugs that reduce the absorption of vitamin K and affect the synthesis of prothrombin, such as various broad-spectrum antibiotics, long-term use of liquid paraffin or cholestyramine (cholestyramine), etc.; ⑷ drugs that can promote the use of this product ⑸ Drugs that bind to platelet receptors, such as quinidine, thyroxine, anabolic steroids, and phenformin; ⑸ Drugs that interfere with platelet function and promote anticoagulation, such as high-dose aspirin, salicylates, prostaglandin synthase inhibitors, chlorpromazine, diphenhydramine, etc.; ⑹ In addition, drugs that can enhance anticoagulation include propylthiouracil, diazoxide, disopyramide, oral hypoglycemic drugs, sulfinpyrazone (anti-gout drugs), etc.; the mechanism is not clear; ⑺ Adrenal cortical hormones and phenytoin sodium can both increase and weaken the anticoagulant effect, and there is a risk of gastrointestinal bleeding. Generally, they are not used together; ⑻ It cannot be used in combination with nekinase and urokinase, otherwise it is easy to cause critical bleeding. 2. Drugs that can weaken the anticoagulant effect when used in combination with this product: ⑴ Inhibit the absorption of oral anticoagulants, including antacids, laxatives, griseofulvin, rifampicin, glutethimide (Daomen Neng), meprobamate (Anning), etc.; ⑵ Vitamin K, oral contraceptives and estrogen, etc., compete with related enzyme proteins and promote the synthesis of factors II, VII, IX, and X.

This product contains acenocoumarol (C19H15NO6). Molecular formula: C19H15NO6 Molecular weight: 353.34

1. Drugs that can enhance the anticoagulant effect when used in combination with this product include: ⑴ drugs that can compete with this product for plasma protein binding, thereby increasing the free amount of di-coumarin, such as aspirin, phenylbutazone, hydroxyphenylbutazone, mefenamic acid, chloral hydrate, clofibrate (clofibrate), sulfonamides, probenecid, etc.; ⑵ drugs that inhibit liver microsomal enzymes, thereby reducing the metabolism of this product and increasing its efficacy, such as chloramphenicol, allopurinol, monoamine oxidase inhibitors, metronidazole (metronidazole), cimetidine, etc.; ⑶ drugs that reduce the absorption of vitamin K and affect the synthesis of prothrombin, such as various broad-spectrum antibiotics, long-term use of liquid paraffin or cholestyramine (cholestyramine), etc.; ⑷ drugs that can promote the use of this product ⑸ Drugs that bind to platelet receptors, such as quinidine, thyroxine, anabolic steroids, and phenformin; ⑸ Drugs that interfere with platelet function and promote anticoagulation, such as high-dose aspirin, salicylates, prostaglandin synthase inhibitors, chlorpromazine, diphenhydramine, etc.; ⑹ In addition, drugs that can enhance anticoagulation include propylthiouracil, diazoxide, disopyramide, oral hypoglycemic drugs, sulfinpyrazone (anti-gout drugs), etc.; the mechanism is not clear; ⑺ Adrenal cortical hormones and phenytoin sodium can both increase and weaken the anticoagulant effect, and there is a risk of gastrointestinal bleeding. Generally, they are not used together; ⑻ It cannot be used in combination with nekinase and urokinase, otherwise it is easy to cause critical bleeding. 2. Drugs that can weaken the anticoagulant effect when used in combination with this product: ⑴ Inhibit the absorption of oral anticoagulants, including antacids, laxatives, griseofulvin, rifampicin, glutethimide (Daomen Neng), meprobamate (Anning), etc.; ⑵ Vitamin K, oral contraceptives and estrogen, etc., compete with related enzyme proteins and promote the synthesis of factors II, VII, IX, and X.

This product contains acenocoumarol (C19H15NO6). Molecular formula: C19H15NO6 Molecular weight: 353.34

1. Drugs that can enhance the anticoagulant effect when used in combination with this product include: ⑴ drugs that can compete with this product for plasma protein binding, thereby increasing the free amount of di-coumarin, such as aspirin, phenylbutazone, hydroxyphenylbutazone, mefenamic acid, chloral hydrate, clofibrate (clofibrate), sulfonamides, probenecid, etc.; ⑵ drugs that inhibit liver microsomal enzymes, thereby reducing the metabolism of this product and increasing its efficacy, such as chloramphenicol, allopurinol, monoamine oxidase inhibitors, metronidazole (metronidazole), cimetidine, etc.; ⑶ drugs that reduce the absorption of vitamin K and affect the synthesis of prothrombin, such as various broad-spectrum antibiotics, long-term use of liquid paraffin or cholestyramine (cholestyramine), etc.; ⑷ drugs that can promote the use of this product ⑸ Drugs that bind to platelet receptors, such as quinidine, thyroxine, anabolic steroids, and phenformin; ⑸ Drugs that interfere with platelet function and promote anticoagulation, such as high-dose aspirin, salicylates, prostaglandin synthase inhibitors, chlorpromazine, diphenhydramine, etc.; ⑹ In addition, drugs that can enhance anticoagulation include propylthiouracil, diazoxide, disopyramide, oral hypoglycemic drugs, sulfinpyrazone (anti-gout drugs), etc.; the mechanism is not clear; ⑺ Adrenal cortical hormones and phenytoin sodium can both increase and weaken the anticoagulant effect, and there is a risk of gastrointestinal bleeding. Generally, they are not used together; ⑻ It cannot be used in combination with nekinase and urokinase, otherwise it is easy to cause critical bleeding. 2. Drugs that can weaken the anticoagulant effect when used in combination with this product: ⑴ Inhibit the absorption of oral anticoagulants, including antacids, laxatives, griseofulvin, rifampicin, glutethimide (Daomen Neng), meprobamate (Anning), etc.; ⑵ Vitamin K, oral contraceptives and estrogen, etc., compete with related enzyme proteins and promote the synthesis of factors II, VII, IX, and X.